Co 1686
- Catalog NO.:A854739
- CAS No. : 1374640-70-6
- Molecular Formula:C27H28F3N7O3
- Molecular Weight: 555.55
Note*
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Bulk Inquiry
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Quality Control&SDS
SDS
Product Details
CAS Number | 1374640-70-6 | Appearance | White solid |
Catalog Number | A854739 | MDL Number | MFCD26793864 |
Molecular Formula | C27H28F3N7O3 | Molecular Weight | 555.55 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | Rociletinib, also known as AVL-301 and CO1686, is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR inhibitor CO-1686 binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors.;NAVL-301; CNX419;-[3-[[2-[[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide;CO-1686 | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H315-H319-H335 | Class | |
Precautionary Statements | P261-P305+P351+P338 | Packing Group |
Description
Rociletinib, also known as AVL-301 and CO1686, is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR inhibitor CO-1686 binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors. |